Results 161 to 170 of about 5,290,284 (268)

NEW PRODUCT DEVELOPMENT [PDF]

open access: yes, 2013
Chuprina, A., Palehova, L.L.
core  

Product Intelligence: Its Conceptualization, Measurement and Impact on Consumer Satisfaction [PDF]

open access: yes
In the last decade, companies have developed a large number of intelligent products. Due to the use of information technology, these products, for example, are able to work autonomously, cooperate with other products, or adapt to changing circumstances ...
Diamantopoulos, A.   +2 more
core   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

New Product Development

open access: yes, 2017
[EN] Product development has been approached by linear methods that apply to any design problem without concern of ambient variables. In this approach, we will find a new matrix method that can deliver a basic path in which the designer can begin his journey, but adaptable to accept ambient variables.
openaire   +2 more sources

Vegetable Waste in the Retail Sector: Evaluation and Possibilities for Use in New Product Development. [PDF]

open access: yesFoods
Chagas EGLD   +5 more
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy